Radiaction Medical Appoints Christopher Barys as United States President and Chief Commercial Officer

October 24, 2023—Radiaction Medical, LTD, an Israel-based medical device company focused on radiation protection for medical staff during interventional procedures, announced that it has appointed industry veteran Christopher Barys to serve as its United States President and Chief Commercial Officer. Barys will lead commercialization efforts and operations in the United States.

Radiaction is a plug-and-play addition to C-arm systems that blocks up to 97% of scatter radiation at the source, offering head-to-toe protection for everyone in the room. Radiaction has received CE Mark approval in Europe and FDA clearance in the United States and is currently being marketed in North America.

The company stated it is currently focused on expanding its footprint in the United States, adding new sites to its user base, and growing its clinical publication pipeline to support the technology’s performance with clinical data, advised Radiaction.

In August 2023, the company announced that Barys joined Radiaction’s Board of Directors. He will remain on the board as he steps into his new role, noted Radiaction in the current press release.

“In the midst of a rapidly changing health care environment, protection for interventional staff has remained stagnant, to the detriment of those health care workers who are in the direct line of harm from scatter radiation,” commented Barys in the latest company press release. “Innovative, clinically supported solutions are needed now more than ever, and Radiaction is answering the call. I am proud to play a key role in its mission to bring forth a new model of advanced radiation protection to the health care providers who need it most.”

Radiaction CEO Jonathan Yifat added, “When we met Chris, I knew he had the right experience and vision to steer Radiaction through our next stage of growth. With his extensive track record of market development within the interventional space, Chris is a tremendous asset to the strategic composition of our leadership team. I am excited to work alongside him in bringing our radiation protection solution to interventional teams across the country.”

In the August press release, the company also announced it had raised $12.6 million in Series C2 funding led by InnovaHealth Partners, a United States private equity fund, with participation from additional coinvestors.